Teleflex (NYSE:TFX) Stock Lifted to Buy by Bank of America

Bank of America upgraded shares of Teleflex (NYSE:TFX) from a neutral rating to a buy rating in a research report report published on Monday morning, Marketbeat Ratings reports. The firm currently has $158.00 price objective on the medical technology company’s stock, up from their previous price objective of $145.00.

Several other research firms also recently weighed in on TFX. Piper Sandler reissued an “overweight” rating and issued a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. UBS Group raised their price target on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st. Zacks Research upgraded Teleflex from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 24th. Finally, BMO Capital Markets started coverage on Teleflex in a report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $155.20.

Teleflex Price Performance

Shares of NYSE:TFX opened at $127.90 on Monday. The company’s fifty day moving average price is $133.87 and its 200 day moving average price is $128.76. Teleflex has a 12 month low of $100.18 and a 12 month high of $145.00. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12. The firm has a market capitalization of $5.42 billion, a P/E ratio of -5.49, a P/E/G ratio of 0.81 and a beta of 0.82.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million during the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. Teleflex’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, sell-side analysts predict that Teleflex will post 7.26 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.34 per share. The ex-dividend date is Friday, August 14th. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. Teleflex’s dividend payout ratio is -5.84%.

Hedge Funds Weigh In On Teleflex

A number of hedge funds and other institutional investors have recently made changes to their positions in TFX. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Teleflex during the 2nd quarter worth approximately $39,467,000. Fifth Third Bancorp increased its holdings in shares of Teleflex by 3,204.8% in the first quarter. Fifth Third Bancorp now owns 68,144 shares of the medical technology company’s stock valued at $8,151,000 after purchasing an additional 66,082 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Teleflex in the second quarter valued at approximately $1,391,000. Irenic Capital Management LP purchased a new stake in shares of Teleflex during the first quarter worth approximately $104,061,000. Finally, Mangrove Partners IM LLC purchased a new stake in shares of Teleflex during the fourth quarter worth approximately $31,331,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Bank of America upgraded Teleflex to Buy from Neutral and raised its price target to $158 from $145. The firm cited improving confidence in Teleflex’s earnings outlook, execution under new leadership and the potential for a 2027 re-rating. BofA Upgrades Teleflex to Buy From Neutral, Adjusts Price Target
• Positive Sentiment: The upgrade reinforces a broader constructive analyst view: recent price targets cited by Quiver Quantitative have a median of $155, with targets ranging from $138 to $160. The higher valuation expectations suggest analysts see meaningful upside as the business becomes more focused. Why Teleflex Stock Is Up Today
• Positive Sentiment: Teleflex’s completed $1.5 billion sale of its OEM business is supporting the bullish case. Management intends to use the proceeds for approximately $800 million of debt reduction and to complete a $1 billion share-repurchase authorization, potentially improving balance-sheet flexibility and per-share value.
• Neutral Sentiment: Analysts characterize 2026 as a transition year, with the slimmer medical-technology-focused company expected to show its fuller earnings potential in 2027. That outlook provides a future catalyst but also means investors may need to wait for the benefits to appear in reported results. Teleflex Growth Prospects and Leadership
• Neutral Sentiment: Recent institutional activity was mixed, with several large funds adding shares while at least one major investor exited its position. This suggests increased interest but does not provide a uniformly bullish signal.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.